Designed to reduce the burden of breast cancer on women and their families

Accelerated Partial Breast Irradiation (APBI) with brachytherapy offers significant advantages: lower toxicities and better cosmesis due to a reduction in total radiation exposure and a reduced treatment duration. Since its introduction in the late 1990s, more than 150,000 women in the U.S. have received ABPI brachytherapy.

  • Demonstrated Efficacy: Cancer control and long-term survival rates similar to EBRT4,5,6,7
  • Minimized Risk of Side Effects: Precision delivery enables surrounding healthy tissues to be spared from unnecessary radiation, reducing toxicity/damage to healthy breast tissue and nearby structures such as the chest wall, heart, lungs or skin8,9,10
  • Preservation of Future Treatment Options: In the case of a tumor recurrence breast conserving therapy can be performed a second time with APBI brachytherapy allowing the breast to still be preserved and avoiding mastectomy10
  • Excellent Cosmesis: Limited fibrosis and skin toxicity, providing excellent cosmetic results8
  • Convenience: The short treatment course (five days or less) allows patients to get back to their routines more quickly11


The innovative strut-based, open-architecture design of the SAVI applicator combines the precise dosimetry of interstitial brachytherapy with the ease and convenience of single-entry devices. With SAVI Brachy, patients receive customized radiation therapy based on their specific anatomy. Unparalleled dose customization:

  • Minimizes dose to normal tissue while maximizing target coverage 12
  • Eliminates skin spacing restrictions 13
  • Reduces the risk of fibrosis and symptomatic seroma 14
  • Expands the number of women eligible for APBI 14

Latest Research & News